{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:53:04Z","timestamp":1792749184712,"version":"4.5.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NS075930"],"award-info":[{"award-number":["RO1NS075930"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NS090905"],"award-info":[{"award-number":["RO1NS090905"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U24NS113452"],"award-info":[{"award-number":["U24NS113452"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL133728"],"award-info":[{"award-number":["R01HL133728"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL142975"],"award-info":[{"award-number":["R01HL142975"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Ischemic stroke is the most widespread cause of disability and a leading cause of death in developed countries. To date, the most potent approved treatment for acute stroke is recanalization therapy with thrombolytic drugs such as tissue plasminogen activator (rt-PA or tPA) or endovascular mechanical thrombectomy. Although tPA and thrombectomy are widely available in the United States, it is currently estimated that only 10\u201320% of stroke patients get tPA treatment, in part due to restrictive selection criteria. Recently, however, tPA and thrombectomy selection criteria have loosened, potentially allowing more patients to qualify. The relatively low rate of treatment may also reflect the perceived risk of brain hemorrhage following treatment with tPA. In translational research and a single patient study, protease activated receptor 1 (PAR-1) targeted therapies given along with thrombolysis and thrombectomy appear to reduce hemorrhagic transformation after recanalization. Such adjuncts may likely enhance the availability of recanalization and encourage more physicians to use the recently expanded selection criteria for applying recanalization therapies. This narrative review discusses stroke therapies, the role of hemorrhagic transformation in producing poor outcomes, and presents the data suggesting that PAR-1 acting agents show promise for decreasing hemorrhagic transformation and improving outcomes.<\/jats:p>","DOI":"10.3389\/fneur.2021.593582","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:16:15Z","timestamp":1615785375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation"],"prefix":"10.3389","volume":"12","author":[{"given":"Patrick D.","family":"Lyden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent E.","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Minigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berislav V.","family":"Zlokovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/CIRCULATIONAHA.109.192667","article-title":"Heart disease and stroke statistics-2010 update: a report from the American Heart Association","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000491","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1161\/CIRCULATIONAHA.105.171600","article-title":"Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tins.2011.01.005","article-title":"Cytoprotective protein C pathways and implications for stroke and neurological disorders","volume":"34","author":"Zlokovic","year":"2011","journal-title":"Trends Neurosci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ana.25383","article-title":"Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke","volume":"85","author":"Lyden","year":"2019","journal-title":"Ann Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMoa1415061","article-title":"Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke","volume":"372","author":"Saver","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1414905","article-title":"Randomized assessment of rapid endovascular treatment of ischemic stroke","volume":"372","author":"Goyal","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa1414792","article-title":"Endovascular therapy for ischemic stroke with perfusion-imaging selection","volume":"372","author":"Campbell","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411587","article-title":"A randomized trial of intraarterial treatment for acute ischemic stroke","volume":"372","author":"Berkhemer","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1056\/NEJMoa1503780","article-title":"Thrombectomy within 8 hours after symptom onset in ischemic stroke","volume":"372","author":"Jovin","year":"2015","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial","volume":"395","author":"Hill","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1056\/NEJMoa1713973","article-title":"Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging","volume":"378","author":"Albers","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1161\/STROKEAHA.111.639211","article-title":"Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+intra-arterial thrombolysis","volume":"43","author":"Mullen","year":"2012","journal-title":"Stroke"},{"key":"B14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1747-4949.2011.00670.x","article-title":"Endovascular treatment strategies for acute ischemic stroke","volume":"6","author":"Ellis","year":"2011","journal-title":"Int J Stroke"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1161\/STROKEAHA.110.595496","article-title":"Can molecular and cellular neuroprotection be translated into therapies for patients? Yes, but not the way we tried it before","volume":"41","author":"Tymianski","year":"2010","journal-title":"Stroke"},{"key":"B16","first-page":"298","article-title":"Angiogenesis, neurogenesis and brain recovery of function following injury","volume":"11","author":"Xiong","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12975-011-0074-4","article-title":"Emerging therapies: pleiotropic multi-target drugs to treat stroke victims","volume":"2","author":"Lapchak","year":"2011","journal-title":"Transl Stroke Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-guided thrombolysis for stroke with unknown time of onset","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1001\/archneur.58.12.2009","article-title":"Intravenous tissue-type plasminogen activator therapy for ischemic stroke: houston experience 1996 to 2000","volume":"58","author":"Grotta","year":"2001","journal-title":"Arch Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11910-009-0076-8","article-title":"Evolution of the thrombolytic treatment window for acute ischemic stroke","volume":"10","author":"Stemer","year":"2010","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ijs.12459","article-title":"Solitaire\u2122 with the Intention for thrombectomy as primary endovascular treatment for acute ischemic stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke","volume":"10","author":"Saver","year":"2015","journal-title":"Int J Stroke"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S1474-4422(16)30177-6","article-title":"Mechanical thrombectomy after intravenous alteplase vs. alteplase alone after stroke (THRACE): a randomised controlled trial","volume":"15","author":"Bracard","year":"2016","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000489566","article-title":"Wake-up stroke vs. stroke with known onset time: clinical and multimodality CT imaging characteristics","volume":"45","author":"Dankbaar","year":"2018","journal-title":"Cerebrovasc Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp.65.1.1","article-title":"Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke","volume":"65","author":"del Zoppo","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","article-title":"The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy","volume":"46","author":"von Kummer","year":"2015","journal-title":"Stroke"},{"key":"B29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/01.STR.25.2.291","article-title":"Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke","volume":"25","author":"Levy","year":"1994","journal-title":"Stroke"},{"key":"B30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/01.STR.0000196942.84707.71","article-title":"Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke","volume":"37","author":"Trouillas","year":"2006","journal-title":"Stroke"},{"key":"B31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/STROKEAHA.116.016368","article-title":"Predictors for symptomatic intracranial hemorrhage after endovascular treatment of acute ischemic stroke","volume":"48","author":"Hao","year":"2017","journal-title":"Stroke"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/01.STR.0000125712.02090.6e","article-title":"In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?","volume":"35","author":"Kent","year":"2004","journal-title":"Stroke"},{"key":"B37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1161\/01.STR.0000251644.76546.62","article-title":"Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian Alteplase for Stroke Effectiveness Study registry","volume":"38","author":"Dzialowski","year":"2007","journal-title":"Stroke"},{"key":"B38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1212\/WNL.0b013e318245d22c","article-title":"Is asymptomatic hemorrhagic transformation really innocuous?","volume":"78","author":"Park","year":"2012","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.06.024","article-title":"Asymptomatic hemorrhagic transformation after acute ischemic stroke: is it clinically innocuous?","volume":"23","author":"Lei","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.02.006","article-title":"Asymptomatic intracerebral hemorrhage may worsen clinical outcomes in acute ischemic stroke patients undergoing thrombectomy","volume":"28","author":"Jiang","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/neurintsurg-2018-013848","article-title":"Prognosis of asymptomatic intracranial hemorrhage after endovascular treatment","volume":"11","author":"Hao","year":"2019","journal-title":"J Neurointerv Surg"},{"key":"B42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00234-018-2141-y","article-title":"Previous chronic symptomatic and asymptomatic cerebral hemorrhage in patients with acute ischemic stroke","volume":"61","author":"Li","year":"2019","journal-title":"Neuroradiology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1385\/MN:28:3:229","article-title":"Triggers and mediators of hemorrhagic transformation in cerebral ischemia","volume":"28","author":"Wang","year":"2003","journal-title":"Mol Neurobiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.3390\/ijms20153675","article-title":"Heme, heme oxygenase, and endoplasmic reticulum stress-a new insight into the pathophysiology of vascular diseases","volume":"20","author":"G\u00e1ll","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"B46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00415-014-7297-8","article-title":"Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis","volume":"261","author":"Tan","year":"2014","journal-title":"J Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1161\/STROKEAHA.117.019193","article-title":"Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy","volume":"48","author":"Zhao","year":"2017","journal-title":"Stroke"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1185\/03007990903196422","article-title":"Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke, or major bleed","volume":"25","author":"Boccuzzi","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"B49","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/jcbfm.2010.184","article-title":"Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing","volume":"31","author":"O'Collins","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1182\/blood-2017-10-810895","article-title":"PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke","volume":"131","author":"Sinha","year":"2018","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1523\/JNEUROSCI.4491-12.2013","article-title":"An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway","volume":"33","author":"Guo","year":"2013","journal-title":"J Neurosci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1160\/th14-05-0448","article-title":"Cytoprotective-selective activated protein C therapy for ischaemic stroke","volume":"112","author":"Mosnier","year":"2014","journal-title":"Thromb Haemost"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1182\/blood-2004-01-0110","article-title":"Activated protein C variants with normal cytoprotective but reduced anticoagulant activity","volume":"104","author":"Mosnier","year":"2004","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1161\/STROKEAHA.112.658997","article-title":"An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents","volume":"43","author":"Wang","year":"2012","journal-title":"Stroke"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1161\/STROKEAHA.113.003350","article-title":"An activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats","volume":"44","author":"Wang","year":"2013","journal-title":"Stroke"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm.4154","article-title":"3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice","volume":"22","author":"Wang","year":"2016","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.2174\/138161212802430413","article-title":"Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for stroke","volume":"18","author":"Williams","year":"2012","journal-title":"Curr Pharm Des"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1474-4422(13)70079-6","article-title":"Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials","volume":"12","author":"Whiteley","year":"2013","journal-title":"Lancet Neurol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(01)05837-8","article-title":"Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial","volume":"358","author":"Bath","year":"2001","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1001\/archneur.1987.00520200052018","article-title":"Intracerebral hemorrhage after experimental embolic infarction: anticoagulation","volume":"44","author":"Lyden","year":"1987","journal-title":"Arch Neurol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2019.03.010","article-title":"Neuroprotection and vasculoprotection using genetically targeted protease-ligands","volume":"1715","author":"Rajput","year":"2019","journal-title":"Brain Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"33022","DOI":"10.1074\/jbc.M705824200","article-title":"Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions","volume":"282","author":"Mosnier","year":"2007","journal-title":"J Biol Chem"},{"key":"B65","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S0049-3848(16)30368-1","article-title":"Activated protein C promotes neuroprotection: mechanisms and translation to the clinic","volume":"141","author":"Griffin","year":"2016","journal-title":"Thromb Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/ATVBAHA.116.308038","article-title":"2016 scientific sessions Sol Sherry distinguished lecturer in thrombosis: thrombotic stroke: neuroprotective therapy by recombinant-activated protein C","volume":"36","author":"Griffin","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2018-02-769026","article-title":"Activated protein C, protease activated receptor 1 and neuroprotection","volume":"132","author":"Griffin","year":"2018","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","article-title":"Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46","volume":"120","author":"Mosnier","year":"2012","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.neuropharm.2017.09.021","article-title":"Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C","volume":"134","author":"Amar","year":"2018","journal-title":"Neuropharmacology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1074\/jbc.C100017200","article-title":"Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis","volume":"276","author":"Joyce","year":"2001","journal-title":"J Biol Chem"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1126\/science.1071699","article-title":"Activation of endothelial cell protease activated receptor 1 by the protein C pathway","volume":"296","author":"Riewald","year":"2002","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nm826","article-title":"Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective","volume":"9","author":"Cheng","year":"2003","journal-title":"Nat Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1182\/blood-2002-12-3680","article-title":"Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1","volume":"101","author":"D\u00f6m\u00f6t\u00f6r","year":"2003","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/bj20030341","article-title":"Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor","volume":"373","author":"Mosnier","year":"2003","journal-title":"Biochem J"},{"key":"B75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/jcbfm.2008.117","article-title":"Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier","volume":"29","author":"Deane","year":"2009","journal-title":"J Cereb Blood Flow Metab"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/j.1538-7836.2012.04825.x","article-title":"Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects","volume":"10","author":"Schuepbach","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B77","doi-asserted-by":"publisher","first-page":"E1372","DOI":"10.1073\/pnas.1112482108","article-title":"Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through \u03b2-arrestin and dishevelled-2 scaffolds","volume":"108","author":"Soh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B78","doi-asserted-by":"publisher","first-page":"702","DOI":"10.18097\/PBMC20146006702","article-title":"Peptide-agonist of protease-activated receptor (PAR 1), similar to activated protein C, promotes proliferation in keratinocytes and wound healing of epithelial layer","volume":"60","author":"Kiseleva","year":"2014","journal-title":"Biomed Khim"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.bbrc.2017.11.174","article-title":"TR47, a PAR1-based peptide, inhibits melanoma cell migration in vitro and metastasis in vivo","volume":"495","author":"de Oliveira","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1182\/blood-2014-06-582775","article-title":"Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity","volume":"124","author":"Stavenuiter","year":"2014","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/blood-2013-03-488957","article-title":"Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3","volume":"122","author":"Burnier","year":"2013","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/jth.12400","article-title":"Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity","volume":"11","author":"Mosnier","year":"2013","journal-title":"J Thromb Haemost"},{"key":"B84","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1471-4159.2009.05921.x","article-title":"Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity","volume":"109","author":"Guo","year":"2009","journal-title":"J Neurochem"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1460-9568.2009.06664.x","article-title":"Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity","volume":"29","author":"Guo","year":"2009","journal-title":"Eur J Neurosci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/nm1122","article-title":"Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C","volume":"10","author":"Liu","year":"2004","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/ana.20602","article-title":"Functional recovery after embolic stroke in rodents by activated protein C","volume":"58","author":"Zlokovic","year":"2005","journal-title":"Ann Neurol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"12788","DOI":"10.1523\/JNEUROSCI.3485-08.2008","article-title":"Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1","volume":"28","author":"Thiyagarajan","year":"2008","journal-title":"J Neurosci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1161\/STROKEAHA.108.536680","article-title":"Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity","volume":"40","author":"Wang","year":"2009","journal-title":"Stroke"},{"key":"B90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.brainres.2010.05.075","article-title":"Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact","volume":"1347","author":"Walker","year":"2010","journal-title":"Brain Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1227\/01.NEU.0000363148.49779.68","article-title":"Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact","volume":"66","author":"Petraglia","year":"2010","journal-title":"Neurosurgery"},{"key":"B92","doi-asserted-by":"publisher","first-page":"127736","DOI":"10.1172\/jci.insight.127736","article-title":"Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons","volume":"5","author":"Shi","year":"2019","journal-title":"JCI Insight"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1172\/JCI38476","article-title":"Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells","volume":"119","author":"Zhong","year":"2009","journal-title":"J Clin Invest"},{"key":"B94","doi-asserted-by":"publisher","first-page":"E1035","DOI":"10.1073\/pnas.1401595111","article-title":"Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice","volume":"111","author":"Winkler","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/nature06559","article-title":"Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets","volume":"451","author":"Han","year":"2008","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1084\/jem.20181035","article-title":"3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice","volume":"216","author":"Lazic","year":"2019","journal-title":"J Exp Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"17286","DOI":"10.1074\/jbc.M412427200","article-title":"Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation","volume":"280","author":"Finigan","year":"2005","journal-title":"J Biol Chem"},{"key":"B98","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/01.RES.0000133680.87668.FA","article-title":"Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo","volume":"95","author":"Uchiba","year":"2004","journal-title":"Circ Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fncel.2015.00344","article-title":"Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke","volume":"9","author":"Amar","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1056\/NEJMoa2000120","article-title":"Thrombectomy for stroke in the public health care system of Brazil","volume":"382","author":"Martins","year":"2020","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1161\/01.STR.0000016923.99605.75","article-title":"Brain hemorrhage after thrombolysis: good or bad?","volume":"33","author":"von Kummer","year":"2002","journal-title":"Stroke"},{"key":"B102","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.annemergmed.2004.12.025","article-title":"Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke","volume":"46","author":"Brown","year":"2005","journal-title":"Ann Emerg Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.593582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:16:19Z","timestamp":1615785379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.593582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":102,"alternative-id":["10.3389\/fneur.2021.593582"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.593582","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"article-number":"593582"}}